Rishik Rangaraju

"ICMR releases draft ethical guidelines for adoption of AI in biomedical research and healthcare." PharmaBiz,
27 Sept. 2022, p. NA. Gale General OneFile,
link.gale.com/apps/doc/A719812189/GPS?u=glen20233&sid=bookmark-GPS&xid=a20d6da7. Accessed 3
Nov. 2022.

This article discusses the growing implementation of artificial intelligence in medicine. A recent example that
was given was that the Indian Council of Medical Research (ICMR) released draft ethical guidelines for the
application of Artificial Intelligence in biomedical research and healthcare. The guidelines for this draft would
apply to any AI based tools for scientific purposes that involve humans and apply to essentially anyone who
wants to utilize health data for biomedical research and healthcare delivery using AI technology and techniques,
such as health professionals, researchers, or technology developers. Many critical challenges in the field of
health have the potential to be solved by AI, such as the screening of patients, complex data analysis, clinical
decision making, and predicting disease outcomes. In the present day, AI technology and machine learning is
being used in the field of drug discovery and epitope (part of an antigen) identification for vaccine development
with the potential of even accelerating this process along with making it more cost effective. The problem of the
shortage of skilled workforce is being solved by AI and Machine Learning by handling large and diverse
datasets in an efficient manner with high accuracy and offering data driven solutions for predicting the risks and
strategies of mitigating diseases. National bills have even been made in India to ensure the security of health
data, such as the Digital Information Security in Healthcare Act (DISHA) and Personal Data Protection bill
(PDP). This article also focuses on the ethical principles of using AI in medicine. This article essentially
concludes that integrating AI into medicine will fix many medical challenges/constraints new policies are
currently being created today to help ensure it to have a safe and secure integration into clinical practices
globally.
The author, Laxmi Yadav, is qualified to discuss ethical guidelines and adoption of AI in biomedical
research and healthcare because her credentials include working a verified academic publication PharmaBiz by
Athena Information Solution, working in the field of Neuroscience, and has a PhD in Behavioral Neuroscience.
Her address for contact information is given in a secure link to PharmaBiz with the phone number of
(022)-2204-0015. Written one month ago, this source is very current on the topic of ethical guidelines for
adoption of AI in biomedical research and healthcare that have been released in nations such as India. The
author of this article thoroughly evaluated all sides of the issue. For example, they acknowledge that AI
technologies are prone to cyber-attacks and can be exploited to get access to sensitive/private information which
threatens the confidentiality of the patients and their data, and then address that opposing viewpoint by saying
that the problem can be resolved by using a robust set of control mechanisms to completely anonymize the data
and to make it offline to prevent this exploitation from cyber-attacks. This inclusion shows that the article’s
author acknowledges alternative viewpoints because she has given out the fact that AI can be vulnerable to data
breaches and is not perfect in this regard which can be considered a flaw, but this can also be prevented with
effort using the given methods to protect the rights and safety of patients. The information contained in the
source can be verified elsewhere. For example, the author says that AI technologies gets further developed and
applied in clinical decision making, which can be corroborated by Nishit Desai in his research work of Clinical
Trials in India as it is stated that automation in clinical trials can range from simple processes such as digitizing
IC procedures to application of artificial intelligence or blockchain technologies at different levels of trials.
Collaboration has also been done for blockchain and AI data solutions during clinical trials by Intel and
ConsenSys Health. The purpose of this article is to show how AI can and is currently being adopted in
biomedical research and healthcare with recent examples of how global policies for such implementation are
being put into place today. The audience is for people who want the current up to date information on specific
policies/actions taken for AI induction in medicine with recent examples. The article is appropriate for this
Rishik Rangaraju

purpose and audience because a specific recent example is given along with general information of the current
process, and it even addresses problems of AI being integrated into medicine. For example, the ICMR (Indian
Council of Medical Research) has recently released ten draft guidelines for adoption of AI in biomedical
research and healthcare which include autonomy, safety, data privacy, optimization of data quality, etc.